<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972722</url>
  </required_header>
  <id_info>
    <org_study_id>YH-S001-05</org_study_id>
    <nct_id>NCT03972722</nct_id>
  </id_info>
  <brief_title>Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer</brief_title>
  <acronym>CC</acronym>
  <official_title>An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Gloria Biosciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Gloria Biosciences Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, uncontrolled, multi-center, phase II study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">May 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>within 27 Months after patient enrolled</time_frame>
    <description>Based on an independent image assessment board</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>within 27 Months after patient enrolled</time_frame>
    <description>meaningful benefit in PFS based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>within 27 Months after patient enrolled</time_frame>
    <description>meaningful benefit in DCR based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>within 27 Months after patient enrolled</time_frame>
    <description>meaningful benefit in DOR based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>within 3 years after patient enrolled.</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>within 27 Months after patient enrolled</time_frame>
    <description>meaningful benefit in TTR based on RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>GLS-010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full-human anti-pd-1 monoclonal antibodies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS-010</intervention_name>
    <description>Patients will be given 240mg GLS-010 every treatment.</description>
    <arm_group_label>GLS-010</arm_group_label>
    <other_name>Full-human anti-pd-1 monoclonal antibodies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willingness to participate in the clinical trial; completely understanding and knowing&#xD;
             about the study and signing the ICF; willingness and capability to comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
          2. Female aged from 18 to 75 years (margin included).&#xD;
&#xD;
          3. Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1).&#xD;
&#xD;
          4. Recurrent or metastatic cervical cancer patients who progress after receiving≥ 1&#xD;
             chemotherapy or are resistant to chemotherapy.&#xD;
&#xD;
          5. Based on RECIST 1.1, at least one measurable lesions, i.e. an extranodal lesion ≥10 mm&#xD;
             in the longest diameter of cross-sectional areas or a lymph node lesion ≥ 15 mm in the&#xD;
             shortest diameter of cross-sectional areas in CT or MRI test.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          7. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          8. Organ and hematopoietic function as defined below:&#xD;
&#xD;
             Hemoglobin (HGB) ≥ 90 g/L; White blood cell (WBC) ≥ 3 X 109/L; Absolute neutrophil&#xD;
             count (ANC) ≥ 1.5 X 109/L; Platelets (PLT) ≥ 100 X 109/L; Total bilirubin≤ 1.5×upper&#xD;
             limit of normal (ULN); AST and ALT ≤ 2.5×ULN or, for hepatic dysfunction due to liver&#xD;
             metastases, ≤ 5×ULN; Serum creatinine (Cr) ≤ 1.5 X ULN or a creatinine clearance&#xD;
             (CrCl) ≥ 50 mL/min; International normalized ratio (INR) or activated partial&#xD;
             thromboplastin time (aPTT)≤1.5×ULN;&#xD;
&#xD;
          9. Female patients of childbearing potential should be willing to birth control after ICF&#xD;
             signing, the course of the study, and 5 months after the last dose of study&#xD;
             medication.&#xD;
&#xD;
         10. Patients must agree to provide either an archival tumor tissue sample or fresh biopsy&#xD;
             sample for baseline biomarker tissue analyses, including staining for PD-L1. If&#xD;
             archival tissue is not available and the patient does not have biopsy-accessible tumor&#xD;
             lesions, the patient will be excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137 or anti-CTLA-4 agent&#xD;
             (including Ipilimumab or any other drug specifically targeting T-cell co-stimulation&#xD;
             or checkpoint pathways).&#xD;
&#xD;
          2. Prior anti-tumor therapy,(including chemotherapy, targeted small molecule therapy ,&#xD;
             radiotherapy, immunotherapy, mAb therapy) , or treatment with investigational products&#xD;
             having not been launched onto the market in China in other clinical trials within 4&#xD;
             weeks prior to the first dose.&#xD;
&#xD;
          3. A past history of allergic reactions attributed to any macromolecular protein&#xD;
             preparation/monoclonal antibody, or any other composition of the investigational&#xD;
             product.&#xD;
&#xD;
          4. Pregnancy or lactation.&#xD;
&#xD;
          5. Patients with any autoimmune disease and received systemic therapy within 2 years&#xD;
             (i.e. corticosteroids or immunosuppressive medications) [i.e.,but not limited to,&#xD;
             uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism,&#xD;
             hypothyroidism (hypothyroidism without clinical symptoms or caused by radiotherapy and&#xD;
             chemotherapy can be included), patients with vitiligo or asthma CR in Childhood, not&#xD;
             requiring any intervention in adulthood are permitted to enroll; patients with asthma&#xD;
             requiring a bronchiectasis intervention are not permitted to enroll].&#xD;
&#xD;
          6. Subjects that requires systemic corticosteroids (dose equivalent to or above 10 mg&#xD;
             prednisone daily) or other immunosuppressive medications within 14 days prior to&#xD;
             enrollment or for the course of the study.&#xD;
&#xD;
          7. Patients with known active central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
          8. Having received a live vaccine within 4 weeks prior to the first dose of&#xD;
             investigational drug.&#xD;
&#xD;
          9. Having received a live anti-tumor vaccine, or anti-tumor treatment with&#xD;
             immunostimulation.&#xD;
&#xD;
         10. Serious medical illness, such as severe infections, uncontrollable diabetes mellitus,&#xD;
             cardiovascular diseases (i.e., grade 3 or 4 congestive heart failure (New York Heart&#xD;
             Association (NYHA)), ≥ grade 2 heart block, myocardial infarction, uncontrolled&#xD;
             arrhythmias, or unstable angina within 6 months prior to screening, and cerebral&#xD;
             infarction within 3 months prior to screening) or lung diseases (i.e. interstitial&#xD;
             pneumonia, obstructive pulmonary disease and symptomatic bronchospasm).&#xD;
&#xD;
         11. Patients with positive HBsAg and/or positive HBcAb with positive hepatitis B virus&#xD;
             DNA&gt; 103 copies/mL, or positive hepatitis C virus antibody; or positive syphilis.&#xD;
&#xD;
         12. A known history of human immunodeficiency virus (HIV) infection, or other acquired and&#xD;
             congenital immune deficiency diseases.&#xD;
&#xD;
         13. A known history of active tuberculosis within 1 year prior to the first dose of&#xD;
             investigational drug.&#xD;
&#xD;
         14. Presence of other malignant cancers within 5 years prior to enrollment. Patients with&#xD;
             cured carcinoma in situ and cured skin basal cell carcinoma or cutaneous squamous cell&#xD;
             carcinoma are eligible.&#xD;
&#xD;
         15. Having undergone allogeneic hematopoietic stem cell transplantation or solid organ&#xD;
             transplantation.&#xD;
&#xD;
         16. Having undergone major surgery (with the exception of baseline tumor biopsy), or&#xD;
             serious trauma within 4 weeks prior to the first dose of therapy.&#xD;
&#xD;
         17. A history of alcoholism or drug abuse within 1 year.&#xD;
&#xD;
         18. A clear history of neurological or mental disorders, i.e. epilepsy, dementia, and poor&#xD;
             compliance&#xD;
&#xD;
         19. Patients with other severe, acute or chronic disease that might increase risk of study&#xD;
             drug use and participation, or laboratory abnormality that might confound the results&#xD;
             of the trial.&#xD;
&#xD;
         20. Subjects not eligible for the study for other reasons, evaluated by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohua Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohua Wu, MD</last_name>
    <phone>8621-6417 5590</phone>
    <email>wu.xh@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohua Wu, MD</last_name>
      <phone>8621-6417 5590</phone>
      <email>wu.xh@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

